Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 1.00 [0.73, 1.37] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 1.39 [1.00, 1.94] | | < 1 | | 0% | 1 study (1/-) | 2.6 % | NA | not evaluable | | important | - |
objective responses (ORR) | 1.00 [0.14, 7.26] | | > 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.62 [0.18, 2.22] | | < 1 | | 0% | 1 study (1/-) | 76.7 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.33 [0.18, 0.63] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.22 [0.01, 4.90] | | < 1 | | 0% | 1 study (1/-) | 82.8 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.49 [0.14, 1.72] | | < 1 | | 0% | 1 study (1/-) | 86.8 % | NA | not evaluable | | non important | - |
SAE (any grade) | 0.69 [0.32, 1.48] | | < 1 | | 0% | 1 study (1/-) | 83.1 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 0.67 [0.24, 1.88] | | < 1 | | 0% | 1 study (1/-) | 77.9 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.05 [0.01, 0.16] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.12 [0.05, 0.26] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.44 [0.01, 13.33] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Increased lipase level TRAE (grade 3-4) | 0.89 [0.05, 14.43] | | < 1 | | 0% | 1 study (1/-) | 53.3 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
hepatitis (Autoimmune) AE (grade 3-4) | 3.61 [0.16, 81.33] | | < 1 | | 0% | 1 study (1/-) | 21.2 % | NA | not evaluable | | non important | - |
Abdominal pain AE (grade 3-4) | 1.19 [0.26, 5.50] | | < 1 | | 0% | 1 study (1/-) | 41.0 % | NA | not evaluable | | non important | - |
Acute kidney injury AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.22 [0.01, 4.90] | | < 1 | | 0% | 1 study (1/-) | 82.8 % | NA | not evaluable | | non important | - |
Arthralgia AE (grade 3-4) | 0.44 [0.01, 13.33] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 1.80 [0.16, 20.18] | | < 1 | | 0% | 1 study (1/-) | 31.9 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 5.48 [0.27, 111.16] | | < 1 | | 0% | 1 study (1/-) | 13.7 % | NA | not evaluable | | non important | - |
Colitis AE (grade 3-4) | 1.79 [0.06, 53.98] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.22 [0.01, 4.90] | | < 1 | | 0% | 1 study (1/-) | 82.8 % | NA | not evaluable | | non important | - |
Dermatitis acneiform AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.17 [0.02, 1.47] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
Dysgeusia AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Dysphonia AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 0.44 [0.01, 13.33] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.61 [0.19, 2.02] | | < 1 | | 0% | 1 study (1/-) | 78.9 % | NA | not evaluable | | non important | - |
Guillain-Barré syndrome AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 0.24 [0.06, 0.91] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 0.44 [0.01, 13.33] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
Infusion-related reaction AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Intestinal perforation AE (grade 3-4) | 0.44 [0.01, 13.33] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
Mucosal inflammation AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Myalgia AE (grade 3-4) | 0.44 [0.01, 13.33] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.04 [0.00, 0.77] | | < 1 | | 0% | 1 study (1/-) | 98.3 % | NA | not evaluable | | non important | - |
Peripheral neuropathy AE (grade 3-4) | 0.44 [0.01, 13.33] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
Peripheral oedema AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Pneumonitis AE (grade 3-4) | 1.79 [0.06, 53.98] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.44 [0.04, 4.93] | | < 1 | | 0% | 1 study (1/-) | 74.6 % | NA | not evaluable | | non important | - |
Rash maculopapular AE (grade 3-4) | 0.44 [0.01, 13.33] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
Sepsis AE (grade 3-4) | 0.22 [0.01, 4.90] | | < 1 | | 0% | 1 study (1/-) | 82.8 % | NA | not evaluable | | non important | - |
Stomatitis AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.89 [0.02, 45.29] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |